Venture Kick
Venture Kick is a private philanthropic initiative based in Zurich, Switzerland, founded in 2007 to support Swiss startups at the pre-seed stage. It provides up to 150,000 Swiss francs in funding and offers structured entrepreneurial training aimed at developing sustainable businesses. Entrepreneurs participate in a competitive process, pitching their ideas up to three times for increasing funding amounts, while receiving valuable feedback from expert juries. To date, Venture Kick has supported 600 startup projects with a total of 24.9 million francs, leading to the incorporation of 454 active companies that have created over 6,000 jobs and attracted approximately 2.49 billion francs in subsequent investments. Companies founded by Venture Kick alumni have notably achieved significant recognition, with 55 percent of the TOP 100 Swiss Startup Award in 2018 represented by these ventures. In 2019, the initiative aimed to allocate 4.35 million francs to support idea-stage projects, facilitating the transition of Swiss scientific innovations to global markets.
Top Stages
Past deals in Medical
Clee Medical
Grant in 2025
Clee Medical specializes in developing innovative neuroimaging and surgical access technologies to improve precision and efficiency in neurosurgery. Their products, which include imaging and sensing systems, provide enhanced access, vision, and navigation within the brain, seamlessly integrating with existing neurosurgical equipment and current surgical routines. This enables healthcare providers to potentially enhance patient outcomes with greater precision.
Scanvio
Grant in 2025
Scanvio offers AI-augmented ultrasound software for faster endometriosis diagnosis, providing expert sonography skills to gynecologists, improving health and surgical education.
BLEEDnFIRE Therapeutics
Grant in 2024
BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments
Shape Biopharmaceuticals
Grant in 2024
Shape Biopharmaceuticals is a biotechnology company that specializes in the development of immunotherapeutic drugs aimed at treating chronic diseases with limited treatment options. The company focuses on advanced protein design and formulation technologies to create a new generation of immunotherapies. By addressing unmet medical needs, Shape Biopharmaceuticals seeks to improve patient outcomes for individuals with genetically driven conditions who lack effective therapeutic alternatives. Through its innovative healthcare solutions, the company aims to provide hope and enhance treatment possibilities for patients facing significant health challenges.
Regenosca
Pre Seed Round in 2024
Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.
Pace Locator
Grant in 2024
Pace Locator is a medical technology company that specializes in developing advanced imaging software. Its flagship product, also named Pace Locator, uses electrocardiogram (ECG) and echocardiogram (ECHO) data to generate 3D maps of the heart. This innovative tool helps healthcare professionals localize the source of cardiac arrhythmias and visualize the location of cardiac implantable electronic device (CIED) leads, enabling faster and more accurate diagnoses.
Procavea Biotech
Grant in 2023
Procavea Biotech specializes in developing a drug delivery platform utilizing non-viral protein cages. This innovative technology is tailored specifically for veterinary professionals, aiming to streamline and improve the efficiency of veterinary practice management. By providing a comprehensive solution, Procavea Biotech enhances the overall effectiveness of veterinary services, allowing practitioners to integrate processes seamlessly and elevate the quality of care offered to their clients.
HeroSupport
Grant in 2023
HeroSupport is a medical device manufacturing company founded in 2019 and based in Veyrier, Geneva. The company specializes in creating medical immobilization devices designed to enhance patient comfort during clinical procedures. Its innovative technology transforms imaging and treatment tables into personalized support solutions, specifically catering to the needs of patients undergoing prone breast radiotherapy. This approach allows patients to benefit from tailored support, eliminating the need for them to adjust to the standard table. By improving patient comfort, HeroSupport enables healthcare providers to deliver more effective and cost-efficient cancer treatment.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
Ocumeda
Grant in 2022
Ocumeda is a telemedical network specializing in ophthalmology, providing accessible eye screening services through collaborations with opticians, retirement homes, and companies. The company employs board-certified ophthalmologists who conduct medical assessments remotely, utilizing a secure cloud platform. Additionally, Ocumeda integrates medical artificial intelligence products to enhance the screening process, enabling opticians and pharmacies to detect conditions that may lead to blindness and vision loss. By lowering barriers to eye examinations, Ocumeda aims to improve overall eye health and accessibility to care.
Maven Health
Non Equity Assistance in 2022
Maven Health is a health technology company that provides an innovative metabolic health solution aimed at healthcare providers. The company employs saliva as the bio-fluid for analyzing metabolites through advanced Nuclear Magnetic Resonance (NMR) spectrometry, utilizing proprietary analytical methods. This approach allows for a comprehensive assessment of individuals' metabolic health with minimal invasiveness and at a competitive cost. By delivering results via an intuitive data platform, Maven Health enables healthcare professionals to effectively identify individuals at risk for metabolic disorders who may not be detected through conventional healthcare practices.
FimmCyte
Grant in 2022
FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on Endometriosis. The company aims to accelerate the path toward a cure for endometriosis by addressing significant healthcare requirements and advancing novel ideas in women's health. FimmCyte's mission is to empower women to take control of their health and meet their unmet medical needs through cutting-edge treatments.
OptimaRatio
Grant in 2022
OptimaRatio liberates chronic and rare disease patients from managing their complex health data.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
NexMR
Grant in 2022
NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.
Simulatory
Grant in 2022
Simulatory is a company that specializes in developing virtual simulators aimed at training surgeons in ultra-minimally invasive endoscopic techniques for spinal surgery. The simulator provides an intuitive workspace that incorporates machine learning and artificial intelligence, allowing for a comprehensive simulation guide. This innovative approach enables surgeons to practice in a safe, data-driven environment, enhancing their skills and proficiency in complex surgical procedures. By leveraging advanced technology, Simulatory aims to improve surgical training outcomes and ultimately contribute to better patient care in spinal surgery.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
NexMR
Grant in 2022
NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.
Adiposs
Seed Round in 2021
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.
Bottneuro
Grant in 2021
Bottneuro is a company focused on developing innovative therapies for early to moderate-stage Alzheimer's Disease patients. Utilizing its proprietary NENI technology platform, Bottneuro creates non-invasive stimulation protocols that target neurons and glial cells in the brain. In addition to its work in Alzheimer's treatment, the company has developed a brain therapy system designed to alleviate chronic neuropathic pain. This system employs plant-based components and features a 3D printed cap that allows for continuous monitoring and targeted delivery of active substances within the body. By addressing the specific needs of patients with early to mild Alzheimer's disease, Bottneuro aims to enhance their quality of life through improved treatment options and medical care.
InnoSpina
Grant in 2021
InnoSpina is a medical device company focused on developing innovative 3D printed implants and specialized surgical guiding instruments for the treatment of chronic back pain. The company's products are designed to facilitate minimally invasive and motion-preserving procedures for spinal disorders. By offering intuitive guiding instruments and novel implants, InnoSpina empowers spine surgeons and interventional pain management specialists to achieve safe and accurate positioning during surgery. This approach not only simplifies the surgical process but also significantly reduces the operative time, allowing for more efficient treatment of patients suffering from back pain.
Nemosia
Grant in 2021
Nemosia is a company focused on the development of positron emission tomography (PET) tracers aimed at diagnosing neurological disorders. Utilizing advanced technology, Nemosia creates tracers that facilitate the early detection of neurodegenerative diseases by visualizing N-methyl-D-aspartate (NMDA) receptors in the brain. This innovative approach allows for timely intervention, enabling patients to take proactive measures against neurological conditions. Through its specialized PET imaging capabilities, Nemosia contributes to improved diagnostic accuracy and better patient outcomes in the field of neurology.
Resmonics
Grant in 2021
Resmonics is a technology company established in October 2020 as a spin-off from ETH Zürich and the University of St. Gallen. The company specializes in developing a privacy-friendly acoustic artificial intelligence system that analyzes soundscapes to detect symptoms of infectious lung diseases. Its flagship product line, Quorum, integrates this AI technology with air quality sensors and noise analytics, aiming to foster healthy and productive environments. Resmonics' technology is particularly focused on chronic disease management, offering solutions for triage and monitoring of nocturnal respiratory symptoms. By providing clinically validated insights and early warnings for respiratory crises through a mobile application, Resmonics enhances patient safety and health management.
Abologix
Debt Financing in 2021
Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.
CustomSurg
Grant in 2021
CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.
aiEndoscopic
Grant in 2021
aiEndoscopic is a MedTech start-up focused on enhancing the safety and simplicity of tracheal intubations through the integration of robotics and artificial intelligence. The company manufactures advanced medical devices that offer visual access and precision, allowing for assistive or autonomous endoscopy. This innovative approach enables surgeons to perform intubation and various surgical procedures more effectively, significantly reducing risks to patients' lives. By streamlining the intubation process, aiEndoscopic aims to improve surgical outcomes and enhance the overall efficiency of medical practices.
Regenosca
Pre Seed Round in 2020
Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.
CustomSurg
Convertible Note in 2020
CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.
4iLabs
Grant in 2020
4iLabs is developing a diagnostic toolbox to support clinicians in the therapy decision-making process for patients with progressed cancer beyond the standard of care.
Axentless
Grant in 2020
Axentless develops software using advanced algorithmic technologies to enable interactive speech therapy practice for stroke victims.
Abologix
Grant in 2020
Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.
CustomSurg
Grant in 2020
CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.
Eldico Scientific
Seed Round in 2020
ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.
Adiposs
Pre Seed Round in 2020
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.
Nutrix
Grant in 2020
Nutrix is a Swiss health-tech company based in Basel, founded in 2019, that specializes in developing innovative healthcare solutions. The company's flagship product is a nanosensor that is placed on the tooth to measure glucose levels in saliva, which communicates data to an external application. This technology not only tracks food intake but also offers dietary recommendations to help prevent diabetes. Nutrix aims to enhance health monitoring through precision medicine by combining advanced AI with wearables and digital coaching. In 2025, the company plans to launch CortiSense, a non-invasive cortisol monitoring sensor, further expanding its range of health monitoring solutions. By providing cost-effective and user-friendly tools, Nutrix seeks to empower individuals to manage their health proactively, reducing the need for frequent medical consultations.
Flowbone
Grant in 2020
Flowbone is a Swiss company based in Lausanne that specializes in the development and promotion of injectable biomaterials aimed at preventing fractures in fragile bones. Its innovative technology focuses on minimal-invasive augmentation, allowing weak bones to strengthen themselves without disrupting natural bone mechanics or blood flow. The company's biomaterials are designed to stimulate the body's self-healing capabilities, addressing the needs of patients with chronic insufficiency fractures and optimizing bone health, particularly in spine surgery. Flowbone's mission is to enhance the quality of life and independence for the elderly, helping them avoid the severe consequences associated with fragility fractures.
Regenosca
Grant in 2020
Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.
MimiX Biotherapeutics
Grant in 2020
MimiX Biotherapeutics Sàrl is a Swiss company founded in 2016 that specializes in biofabrication technology focused on tissue manufacturing for therapeutic and diagnostic applications. Based in La Tène, the company aims to revolutionize regenerative and personalized medicine through its innovative point-of-care approach. By developing ultra-fast biomanufacturing technology, MimiX Biotherapeutics seeks to create patient-specific biological tissue equivalents, facilitating tailored treatments that meet individual medical needs.
STIMIT
Pre Seed Round in 2020
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.
Genknowme
Pre Seed Round in 2020
Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.
EarlySight
Grant in 2020
EarlySight SA is a Swiss medical device company established in 2016 and headquartered in Lausanne. It specializes in developing advanced imaging technology to aid in the early detection and treatment of eye diseases. The company's innovative eye fundus camera utilizes cellular-level imaging and transscleral illumination to provide detailed images of the retina, allowing for the detection of minor structural changes. This technology enables eye specialists to monitor treatment effects rapidly and non-invasively, enhancing their ability to visualize the morphology of retinal cells. EarlySight aims to bring its cutting-edge solutions to clinics, thereby improving patient outcomes in ophthalmology.
SurgeonsLab
Grant in 2020
SurgeonsLab is a Swiss company founded in 2020, based in Bern, that specializes in developing and producing patient-specific training models for surgical procedures and validating new medical devices. The company focuses on microsurgery and micro-interventions, offering solutions for treatment planning and strategy. SurgeonsLab's innovative devices are designed to enhance precision in surgeries and clinical interventions, enabling medical trainees to improve their skills through high-end technology that serves as an alternative to traditional human and animal models. By facilitating testing and planning for surgical interventions, SurgeonsLab aims to ultimately enhance patient safety and outcomes in the medical field.
Selph
Grant in 2020
Selph is a medical technology company that focuses on developing a medical device that enables people to conduct a self-test for sexually transmitted diseases. It specializes in digital health, sensors, diagnostics, and medical services.
Inanna Fertility
Grant in 2020
Inanna Fertility develops a clinical decision support platform designed to enhance the outcomes of in-vitro fertilization treatments. The company's innovative platform utilizes machine learning algorithms and a comprehensive global patient database to deliver data-driven insights that facilitate personalized treatment recommendations. These recommendations are dynamically adjusted according to each patient's unique medical history and response to treatment. By providing this tailored support, Inanna aims to alleviate the physical, emotional, and financial burdens faced by couples undergoing fertility treatments, positioning itself as a leader in the realm of fertility clinic solutions.
Terapet
Grant in 2020
Terapet SA is a Switzerland-based company founded in 2019 at CERN by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals. The company specializes in developing advanced proton therapy technology for cancer treatment, which allows for precise targeting of tumors while minimizing damage to surrounding healthy tissue. This innovative approach leverages the unique properties of protons, which stop at a predetermined depth within the patient, enabling the delivery of a concentrated dose to the tumor. Terapet's system also provides real-time, three-dimensional monitoring of the proton dose administered, enhancing treatment accuracy and safety. With a focus on making cutting-edge cancer therapy more accessible and cost-effective, Terapet is preparing for the market launch of its initial product.
Testmate Health
Grant in 2020
Testmate Health is a medtech startup and an award-winning spin-off from the University of Geneva, Switzerland. The company has developed a smartphone-compatible platform that offers a test kit capable of diagnosing diseases with identifiable DNA or RNA sequences without laboratory involvement, providing rapid results at home in minutes. Their initial product is a user-friendly, all-in-one kit that serves as the first rapid urine self-test for the four most common sexually transmitted diseases (STDs). Given that one million new STDs are diagnosed daily, Testmate Health addresses a critical gap in the market, as traditional testing often requires lab processing and can take up to a week for results. The kit not only delivers immediate results but also allows users to scan their results with a smartphone, facilitating quick access to treatment if necessary. Additionally, Testmate Health has plans to expand its offerings with test kits for other diseases, empowering individuals to manage their health conveniently from home.
Endotelix
Seed Round in 2020
Endotelix is a privately held Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating diagnostic products and therapies aimed at detecting circulating antibodies associated with the condition. By providing fast, sensitive, and reliable diagnostic tests, Endotelix aims to enhance healthcare outcomes for vulnerable populations, including pregnant women and adolescent children. The company is committed to reducing pregnancy-related complications and improving overall healthcare delivery through its advanced research and diagnostic tools.
Swiss Medical Union
Grant in 2020
Swiss Medical Union SA is a healthcare technology company based in Yverdon-les-Bains, Switzerland, founded in 2019. The company specializes in the manufacture of Micro-Bioreactors, which are used to test the interaction, efficiency, and safety of new medical products using models of human organs and tissues. This innovative equipment enables the selection of appropriate therapies ex vivo tailored to individual patient needs. In addition to its bioreactor technology, Swiss Medical Union develops software that simulates the activity of multiple organs, facilitating real-time analysis of interactions between active products and specific human organs. This technology allows monitoring of the effects of injected products within the circulatory system. The company also offers clinical testing services to hospitals, healthcare institutions, government clients, and international clinical facilities, supporting medical professionals in making informed decisions, particularly in cancer treatment.
MaxWell Biosystems
Grant in 2019
MaxWell Biosystems AG is an electronics and biotechnology company headquartered in Zurich, Switzerland, established in 2016. The company specializes in advancing neuroscience research and enhancing preclinical drug discovery through its innovative instrumentation. Its flagship product, MaxOne, is a sophisticated electrophysiology platform that features a high-density microelectrode array with 26,400 electrodes, enabling the recording and stimulation of electrogenic cells in vitro. This platform is equipped with 1024 low-noise readout channels and 32 stimulation channels, facilitating the extraction of both single-cell and network parameters. By utilizing this technology, MaxWell Biosystems significantly reduces the time required for characterizing cell functions, enabling researchers to complete processes that previously took several months in just a few weeks.
anavo medical
Grant in 2019
Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.
Adiposs
Pre Seed Round in 2019
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.
Eldico Scientific
Grant in 2019
ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.
4i Labs
Grant in 2019
4i Labs generates multiplexed images of biological samples for molecular view of tumours.
OxyPrem
Pre Seed Round in 2019
OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.
Microcaps
Pre Seed Round in 2019
Microcaps AG is a company based in Zurich, Switzerland, founded in 2018, specializing in the development of advanced microencapsulation technology. The firm focuses on creating devices that facilitate the precise production of monodisperse microcapsules and microparticles through innovative microfluidics. Microcaps' solutions are designed to enhance drug delivery systems and probiotic encapsulation, while also providing tailored offerings for various applications, including pharmaceuticals and cosmetics. Their cutting-edge technology enables scalable, fully-automated production that allows for size control, precise dosing, and improved stability of the encapsulated materials. By utilizing a step emulsification device, Microcaps enhances production capacity and throughput rates without compromising quality, making it a pivotal player in the field of microencapsulation.
OxyPrem
Seed Round in 2019
OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.
Endotelix
Pre Seed Round in 2019
Endotelix is a privately held Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating diagnostic products and therapies aimed at detecting circulating antibodies associated with the condition. By providing fast, sensitive, and reliable diagnostic tests, Endotelix aims to enhance healthcare outcomes for vulnerable populations, including pregnant women and adolescent children. The company is committed to reducing pregnancy-related complications and improving overall healthcare delivery through its advanced research and diagnostic tools.
Alibion
Grant in 2019
Alibion AG is a therapeutics development company founded in 2018 and located in Allschwil, Switzerland. The company aims to bridge the gap between academic drug discoveries and patient access by accelerating the early-stage development of novel therapeutics. Recognizing that many promising therapies developed in academic settings often fail to progress to preclinical and clinical testing due to a lack of development partners, Alibion focuses on identifying and advancing these innovative compounds. By pooling necessary resources and managing drug development through outsourced partners, Alibion seeks to streamline processes, reduce costs, and ensure compliance with quality standards. Ultimately, the company is dedicated to improving patient outcomes globally by facilitating the transition of new therapies from labs to late-stage development.
anavo medical
Grant in 2019
Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.
Adiposs
Grant in 2019
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at improving early detection of cachexia, a severe body-wasting syndrome often associated with cancer. The company's first-in-class CT contrast product is designed to identify signs of body wasting a year before noticeable weight loss occurs, allowing healthcare providers to detect cancer at an earlier stage. This advancement not only enhances the quality of life for patients but also increases their chances of survival against cancer and other chronic diseases. Through its pioneering imaging technology, Adiposs is positioned to make a significant impact in the field of oncology and patient care.
STIMIT
Grant in 2019
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.
Genknowme
Grant in 2019
Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.
Endotelix
Grant in 2019
Endotelix is a privately held Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating diagnostic products and therapies aimed at detecting circulating antibodies associated with the condition. By providing fast, sensitive, and reliable diagnostic tests, Endotelix aims to enhance healthcare outcomes for vulnerable populations, including pregnant women and adolescent children. The company is committed to reducing pregnancy-related complications and improving overall healthcare delivery through its advanced research and diagnostic tools.
Hi-D Imaging
Grant in 2019
Hi-D Imaging AG is a Swiss company established in 2019, specializing in advanced imaging technologies for cardiovascular disease, particularly focusing on heart valve replacement. The company offers a SaaS-based pre-operational planning platform that assesses the hemodynamics of patient-specific anatomies. This platform enables physicians to analyze blood flow patterns and select the optimal size and shape of heart valves prior to trans-catheter aortic valve implantation. By providing detailed imaging and in-vitro fluid dynamic analysis, Hi-D Imaging empowers medical professionals to make data-driven decisions tailored to individual patient needs, thereby improving surgical outcomes and reducing the necessity for additional medical imaging. The company is headquartered in Winterthur, Switzerland.
B-rayZ
Grant in 2019
B-rayZ is a company that originated as a spin-off from the University Hospital Zurich, focusing on the intersection of artificial intelligence and medical imaging. Comprising a team of professional radiologists, data scientists, and physicians with extensive experience in radiology, B-rayZ specializes in developing predictive deep learning analytical tools and algorithms. Their software is designed to assist radiologists specifically in the area of mammography, providing real-time assessments of image quality and breast density. This technology facilitates accurate and standardized evaluations of medical imaging data, ultimately enhancing breast cancer detectability. By equipping specialists with intelligent tools, B-rayZ aims to improve the detection of breast cancer while also contributing to the reduction of healthcare costs.
Microcaps
Grant in 2018
Microcaps AG is a company based in Zurich, Switzerland, founded in 2018, specializing in the development of advanced microencapsulation technology. The firm focuses on creating devices that facilitate the precise production of monodisperse microcapsules and microparticles through innovative microfluidics. Microcaps' solutions are designed to enhance drug delivery systems and probiotic encapsulation, while also providing tailored offerings for various applications, including pharmaceuticals and cosmetics. Their cutting-edge technology enables scalable, fully-automated production that allows for size control, precise dosing, and improved stability of the encapsulated materials. By utilizing a step emulsification device, Microcaps enhances production capacity and throughput rates without compromising quality, making it a pivotal player in the field of microencapsulation.
OxyPrem
Grant in 2018
OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.
Aspivix
Seed Round in 2018
Aspivix SA is a Swiss company founded in 2015, specializing in the development of minimally invasive surgical instruments for gynecology. Headquartered in Lausanne, the firm focuses on creating a new generation of medical devices that enhance the safety and comfort of gynecological procedures. Its flagship product, CAREVIX, employs innovative suction technology to facilitate the painless placement of intra-uterine contraceptive devices and other gynecological interventions. This device is specifically designed to reduce cervical bleeding and minimize the risk of lesions and cross-infections, ultimately safeguarding patient health. By replacing traditional methods such as the use of forceps with its patented suction pad technology, Aspivix aims to transform gynecological care, providing gentler solutions for both women and healthcare providers.
SEED Biosciences
Pre Seed Round in 2018
SEED Biosciences SA, founded in 2018 and based in Renens, Switzerland, is an award-winning startup specializing in innovative solutions for single-cell assays. The company develops DispenCell, a compact pipetting robot designed to enable scientists to precisely isolate single cells. This technology is crucial for various biological processes, including the production of biologics, cancer diagnosis, stem cell therapies, and personalized medicine.
MOMM Diagnostics
Grant in 2018
MOMM Diagnostics is a Swiss company based in Basel, established in 2018, that specializes in the development of innovative diagnostic devices for the early diagnosis of preeclampsia, a serious condition affecting pregnant women. The company focuses on creating in-vitro diagnostic tests that can be utilized at the point of care, allowing for timely detection and intervention. By providing rapid diagnostic solutions, MOMM Diagnostics aims to enhance the quality of care for expectant mothers and improve health outcomes related to preeclampsia.
ONtrack Diagnostics
Grant in 2018
ONtrack Diagnostics is a medical technology company based in Zurich, Switzerland, that specializes in creating non-invasive assays aimed at the screening, diagnosis, and monitoring of oncological diseases. The company's initial product is a urine assay designed specifically for the screening of prostate cancer. By focusing on innovative diagnostic solutions, ONtrack Diagnostics seeks to improve patient outcomes in the field of oncology.
EBAMed
Seed Round in 2018
EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.
OxyPrem
Grant in 2018
OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.
Volumina Medical
Pre Seed Round in 2018
Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of advanced tissue reconstruction technologies tailored for the reconstructive and plastic surgery markets. The company focuses on tissue engineering, creating injectable 3D scaffolds that facilitate the reconstruction of lost soft tissue volumes due to tumor ablation, disease, trauma, or aesthetic needs. These innovative scaffolds can be administered through thin cannulas, which helps reduce both intervention and recovery times for patients, addressing the challenges associated with the natural repair of three-dimensional soft tissues.
Clemedi
Grant in 2018
Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.
Microcaps
Grant in 2018
Microcaps AG is a company based in Zurich, Switzerland, founded in 2018, specializing in the development of advanced microencapsulation technology. The firm focuses on creating devices that facilitate the precise production of monodisperse microcapsules and microparticles through innovative microfluidics. Microcaps' solutions are designed to enhance drug delivery systems and probiotic encapsulation, while also providing tailored offerings for various applications, including pharmaceuticals and cosmetics. Their cutting-edge technology enables scalable, fully-automated production that allows for size control, precise dosing, and improved stability of the encapsulated materials. By utilizing a step emulsification device, Microcaps enhances production capacity and throughput rates without compromising quality, making it a pivotal player in the field of microencapsulation.
Qnami
Seed Round in 2018
Qnami AG is a Swiss company that specializes in the development of quantum sensing technologies for non-invasive magnetic imaging at the nanoscale. Founded in 2017 and based in Basel, Qnami's flagship products include the ProteusQ, a magnetic imaging microscope, and the Quantum Diamond, which features diamond probes with a single nitrogen-vacancy center for high-resolution imaging. These technologies allow for advanced applications in various fields, including multiferroic antiferromagnets, magnetic random-access memory (MRAM), and superconductivity. By enabling researchers and industries to measure electric and magnetic fields with exceptional sensitivity, Qnami enhances the capabilities of imaging techniques and supports groundbreaking scientific studies and industrial advancements.
DocsVisit
Grant in 2018
DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. By leveraging machine learning, artificial intelligence, and advanced search algorithms, the platform tracks locally available caregivers and enables patients to easily find and book appointments for medical checkups at home. This innovative approach streamlines the process of accessing private medical care, allowing patients to connect with qualified doctors and physicians who offer home visit services.
SEED Biosciences
Grant in 2018
SEED Biosciences SA, founded in 2018 and based in Renens, Switzerland, is an award-winning startup specializing in innovative solutions for single-cell assays. The company develops DispenCell, a compact pipetting robot designed to enable scientists to precisely isolate single cells. This technology is crucial for various biological processes, including the production of biologics, cancer diagnosis, stem cell therapies, and personalized medicine.
ONtrack Diagnostics
Grant in 2018
ONtrack Diagnostics is a medical technology company based in Zurich, Switzerland, that specializes in creating non-invasive assays aimed at the screening, diagnosis, and monitoring of oncological diseases. The company's initial product is a urine assay designed specifically for the screening of prostate cancer. By focusing on innovative diagnostic solutions, ONtrack Diagnostics seeks to improve patient outcomes in the field of oncology.
Aspivix
Grant in 2018
Aspivix SA is a Swiss company founded in 2015, specializing in the development of minimally invasive surgical instruments for gynecology. Headquartered in Lausanne, the firm focuses on creating a new generation of medical devices that enhance the safety and comfort of gynecological procedures. Its flagship product, CAREVIX, employs innovative suction technology to facilitate the painless placement of intra-uterine contraceptive devices and other gynecological interventions. This device is specifically designed to reduce cervical bleeding and minimize the risk of lesions and cross-infections, ultimately safeguarding patient health. By replacing traditional methods such as the use of forceps with its patented suction pad technology, Aspivix aims to transform gynecological care, providing gentler solutions for both women and healthcare providers.
Mirrakoi
Pre Seed Round in 2018
Mirrakoi SA is a Swiss company specializing in the development of computer-aided design software, particularly for the medical field. Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, Mirrakoi offers an innovative solution known as Rhino3DMedical. This proprietary software facilitates a streamlined workflow that allows users to view, analyze, and segment medical images, ultimately creating 3D-printable anatomical models from CT and MRI scans. The technology is designed for orthopedic surgical planning, enabling the development of patient-specific models with ease through an intuitive interface and guided workflow. Mirrakoi's focus on enhancing the design process in the medical sector positions it as a leader in augmented design technology.
EBAMed
Grant in 2018
EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.
Volumina Medical
Grant in 2018
Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of advanced tissue reconstruction technologies tailored for the reconstructive and plastic surgery markets. The company focuses on tissue engineering, creating injectable 3D scaffolds that facilitate the reconstruction of lost soft tissue volumes due to tumor ablation, disease, trauma, or aesthetic needs. These innovative scaffolds can be administered through thin cannulas, which helps reduce both intervention and recovery times for patients, addressing the challenges associated with the natural repair of three-dimensional soft tissues.
DocsVisit
Grant in 2018
DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. By leveraging machine learning, artificial intelligence, and advanced search algorithms, the platform tracks locally available caregivers and enables patients to easily find and book appointments for medical checkups at home. This innovative approach streamlines the process of accessing private medical care, allowing patients to connect with qualified doctors and physicians who offer home visit services.
Clemedi
Grant in 2018
Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.
Rapid Graft
Grant in 2018
Rapid Graft, established in 2018 and based in Zurich, Switzerland, specializes in developing innovative medical devices for precise skin graft harvesting. Their flagship product is a novel dermatome designed to efficiently obtain small split-skin grafts, aiming to enhance chronic wound treatment and facilitate future tissue engineering needs. The company's device enables surgeons to perform skin grafting procedures more effectively, minimizing the risk of infection, scarring, and requiring fewer specialized interventions or operating room resources.
SEED Biosciences
Grant in 2018
SEED Biosciences SA, founded in 2018 and based in Renens, Switzerland, is an award-winning startup specializing in innovative solutions for single-cell assays. The company develops DispenCell, a compact pipetting robot designed to enable scientists to precisely isolate single cells. This technology is crucial for various biological processes, including the production of biologics, cancer diagnosis, stem cell therapies, and personalized medicine.
Qnami
Grant in 2018
Qnami AG is a Swiss company that specializes in the development of quantum sensing technologies for non-invasive magnetic imaging at the nanoscale. Founded in 2017 and based in Basel, Qnami's flagship products include the ProteusQ, a magnetic imaging microscope, and the Quantum Diamond, which features diamond probes with a single nitrogen-vacancy center for high-resolution imaging. These technologies allow for advanced applications in various fields, including multiferroic antiferromagnets, magnetic random-access memory (MRAM), and superconductivity. By enabling researchers and industries to measure electric and magnetic fields with exceptional sensitivity, Qnami enhances the capabilities of imaging techniques and supports groundbreaking scientific studies and industrial advancements.
ABCDx
Grant in 2018
ABCDx SA is a privately-funded company based in Geneva, Switzerland, founded in 2014 by three experts in the field of brain biomarkers. The founders include two prominent researchers from the Faculty of Medicine at the University of Geneva and the Vall d’Hebron Research Institute, who are recognized for their contributions to biomarker discovery and validation. The third founder brings extensive experience in the diagnostic and pharmaceutical industries. ABCDx specializes in the development and validation of biomarker and biomarker panel tests aimed at enhancing the diagnosis and treatment of brain injuries. The company's offerings are designed to identify and assess patients at risk of severe long-term complications stemming from traumatic injuries, strokes, and post-stroke infections. Through its innovative approach, ABCDx aims to improve patient outcomes in the realm of brain health.
Aspivix
Grant in 2017
Aspivix SA is a Swiss company founded in 2015, specializing in the development of minimally invasive surgical instruments for gynecology. Headquartered in Lausanne, the firm focuses on creating a new generation of medical devices that enhance the safety and comfort of gynecological procedures. Its flagship product, CAREVIX, employs innovative suction technology to facilitate the painless placement of intra-uterine contraceptive devices and other gynecological interventions. This device is specifically designed to reduce cervical bleeding and minimize the risk of lesions and cross-infections, ultimately safeguarding patient health. By replacing traditional methods such as the use of forceps with its patented suction pad technology, Aspivix aims to transform gynecological care, providing gentler solutions for both women and healthcare providers.
SNAQ
Grant in 2017
SNAQ GmbH is a Zurich-based company specializing in mobile applications that utilize machine learning and computer vision for food recognition and portion size calculation. The application allows users to send images of their meals, identifying each food item and determining its portion size. By linking this information with a comprehensive nutrition database, SNAQ provides detailed nutritional insights, including carbohydrate, calorie, and protein content for various meals. The company's innovative end-to-end solution has garnered attention and has been showcased at several diabetes conferences across Europe, demonstrating its commitment to enhancing health and lifestyle through technology.
Retinai
Seed Round in 2017
RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.
APERI Pharmaceuticals
Grant in 2017
APERI pharmaceuticals is a biotech in the launch phase developed around an oral biologics delivery platform. With already 2 patents filed and about 7 years of specific research and development we initially target the lucrative Rheumatoid arthritis market with an oral formulation of Adalimumab antibody (Humira). AP09 is a novel permeation enhancer and forms the cornerstone of our technology. It allows macromolecules to diffuse through the tight space between cells, known as tight junctions, where they won’t do it under normal conditions. AP09 adopts a unique, mechanism-based, target selective, trans-mucosal permeation enhancers that offer maximum safety index, highly reversible effect and can transport antibodies without causing any toxicity.
EBAMed
Grant in 2017
EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.
Mirrakoi
Grant in 2017
Mirrakoi SA is a Swiss company specializing in the development of computer-aided design software, particularly for the medical field. Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, Mirrakoi offers an innovative solution known as Rhino3DMedical. This proprietary software facilitates a streamlined workflow that allows users to view, analyze, and segment medical images, ultimately creating 3D-printable anatomical models from CT and MRI scans. The technology is designed for orthopedic surgical planning, enabling the development of patient-specific models with ease through an intuitive interface and guided workflow. Mirrakoi's focus on enhancing the design process in the medical sector positions it as a leader in augmented design technology.
Liberty MedTech
Grant in 2017
Liberty MedTech will solve a vital problem to all person affected with mobility problem with a simple revolutionary solution.
Volumina Medical
Grant in 2017
Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of advanced tissue reconstruction technologies tailored for the reconstructive and plastic surgery markets. The company focuses on tissue engineering, creating injectable 3D scaffolds that facilitate the reconstruction of lost soft tissue volumes due to tumor ablation, disease, trauma, or aesthetic needs. These innovative scaffolds can be administered through thin cannulas, which helps reduce both intervention and recovery times for patients, addressing the challenges associated with the natural repair of three-dimensional soft tissues.
Aesyra
Grant in 2017
Aesyra SA is a Swiss company founded in 2017 and headquartered in Lausanne. It specializes in the design and manufacture of medical devices, particularly the AesyBite, an intra-oral sensor that monitors and alleviates sleep bruxism. Aesyra's technology is aimed at assisting dental professionals by reducing damage to dental prostheses caused by occlusal issues. The company focuses on enhancing the care of individuals with sleep disorders by providing tools that perform intraoral measurements during sleep. These measurements help in detecting bruxism, obstructive sleep apnea, and other related conditions. Through its innovative solutions, Aesyra enables healthcare professionals to accurately monitor patient activities and implement biofeedback treatments to improve sleep quality.
Qnami
Grant in 2017
Qnami AG is a Swiss company that specializes in the development of quantum sensing technologies for non-invasive magnetic imaging at the nanoscale. Founded in 2017 and based in Basel, Qnami's flagship products include the ProteusQ, a magnetic imaging microscope, and the Quantum Diamond, which features diamond probes with a single nitrogen-vacancy center for high-resolution imaging. These technologies allow for advanced applications in various fields, including multiferroic antiferromagnets, magnetic random-access memory (MRAM), and superconductivity. By enabling researchers and industries to measure electric and magnetic fields with exceptional sensitivity, Qnami enhances the capabilities of imaging techniques and supports groundbreaking scientific studies and industrial advancements.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.